Publicacións nas que colabora con Manuel Valladares Ayerbes (30)

2024

  1. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

2022

  1. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

    British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2020

  1. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

    Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267

2018

  1. Hakai overexpression effectively induces tumour progression and metastasis in vivo

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis

    Journal of Cancer Research and Therapeutics, Vol. 13, Núm. 2, pp. 240-245

  2. Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System

    Journal of Proteome Research, Vol. 16, Núm. 8, pp. 2773-2788

2015

  1. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

    BMC Cancer, Vol. 15, Núm. 1

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

2014

  1. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

    Future Oncology, Vol. 10, Núm. 7, pp. 1187-1202

2013

  1. Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: A retrospective study

    Anticancer Research, Vol. 33, Núm. 9, pp. 4089-4096

  2. ¿bevacizumab hasta la progresión?

    Revisiones en Cancer, Vol. 27, pp. 102-105

2012

  1. Circulating MicroRNAs: Molecular microsensors in gastrointestinal cancer

    Sensors (Switzerland), Vol. 12, Núm. 7, pp. 9349-9362

  2. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

    Journal of Translational Medicine, Vol. 10, Núm. 1

  3. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer

    International Journal of Molecular Sciences, Vol. 13, Núm. 4, pp. 4367-4387

2011

  1. Fructose transporter GLUT5 expression in clear renal cell carcinoma

    Oncology Reports, Vol. 25, Núm. 2, pp. 315-323

  2. New insights into molecular mechanisms of sunitinib-associated side effects

    Molecular Cancer Therapeutics, Vol. 10, Núm. 12, pp. 2215-2223

  3. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

    International Journal of Oncology, Vol. 39, Núm. 5, pp. 1253-1264

  4. Tratamiento adyuvante del cáncer de colon en estadio III

    Revisiones en Cancer, Vol. 25, Núm. 2, pp. 53-61